NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer

Inclusion Criteria: * Histologically confirmed small cell lung cancer histology with CNS metastases * Parenchymal disease, ten or less lesions, and supratentorial * PS 70% or greater * Prior CNS radiotherapy. * No previous or currently active second malignancy * Age \> 22 years. * Life expectancy of ≥ 3 months. Exclusion Criteria: * Significant liver function impairment - AST or ALT \> 3 times the upper limit of normal; Total bilirubin \> upper limit of normal. * Significant renal impairment (serum creatinine \> 1.7 mg/dL). * Coagulopathy (as evidenced by PT or APTT \>1.5 times in control patients not undergoing anticoagulation).Thrombocytopenia (platelet count \< 100 x 103/μL). * Neutropenia (absolute neutrophil count \< 1 x 103/μL). * Anemia (Hb \< 10 g/L). * Severe acute infection. Serious non-healing wound or ulcer on scalp * Significant co-morbidities within 4 weeks prior to enrollment. * Implanted pacemaker, defibrillator or deep brain stimulator, or documented clinically significant arrhythmias. * Active implanted medical device (e.g. deep brain stimulators, spinal cord stimulators, vagus nerve stimulators, pacemakers, defibrillators, and programmable shunts). * Skull defect (e.g. missing bone with no replacement). * Shunt * Bullet fragments * Evidence of increased intracranial pressure (midline shift \> 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness). * Sensitivity to conductive hydrogels. * Pregnant or lactating women